Q4 2024 Arcticzymes Technologies ASA Earnings Call Transcript
Key Points
- ArcticZymes Technologies ASA (STU:B4V) reported a significant improvement in EBITDA for Q4 2024, reaching NOK2.7 million compared to the previous year.
- The company successfully launched new SAN HQ neo GMP nucleases and an ELISA kit, enhancing their product offerings.
- A new ERP system was implemented, expected to improve long-term operational efficiencies and support scaling.
- The commercial transformation is underway, with a restructured team aimed at driving growth in 2025.
- Strategic partnerships are progressing, including a collaboration with a leading viral vector CDMO to implement M-SANQ nuclease.
- Total revenue for Q4 2024 was NOK26.4 million, down from NOK29.1 million in Q4 2023.
- Market conditions in 2024, particularly in bioprocessing of advanced therapies, were challenging.
- The average order value decreased by 5.1%, indicating smaller initial purchases from new customers.
- The company faced headwinds from three major accounts, impacting sales performance.
- The ERP project incurred significant costs, impacting operating expenses for the year.
Good morning and welcome to Arcticzymes Q4 presentation 2024. My name is Michael Akoh, I'm the CEO of Arcticzymes, and I'm going to take you through the start of this presentation. I'm joined by Børge Sørvoll, our CFO, as well as our VP of Sales, Paul Blackburn. Thank you for spending your morning with us. Next slide. Just a quick overview of our company to the new ones on board.
Next slide please, Børge. The agenda of today is that I'm going to take you through the highlights of Q4. Then I'm going to talk a bit about 2024 year in review, and then I'm going to recap our strategic priorities. Then Paul is going to take over and share our commercial transformation progress. Paul joined the company in September last year, and he's a key part of our leadership team and a key ingredient in having the commercial transformation that we are executing on. Paul is also going to take you through the sales for Q4.
With our two segments, bio manufacturing and molecular tools. Then Børge is going to move on and go through the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
